Spots Global Cancer Trial Database for A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
Official Title: A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
Study ID: NCT03343613
Study Description
Brief Summary: The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
IU Simon Cancer Center, Indianapolis, Indiana, United States
Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
Tennessee Oncology PLLC, Nashville, Tennessee, United States
Institut Jules Bordet, Brussel, , Belgium
Universitair Ziekenhuis Antwerpen, Edegem, , Belgium
Universitair Ziekenhuis Gent, Gent, , Belgium
Finsen Institute, Copenhagen, , Denmark
Gustave Roussy, Villejuif Cedex, , France
Azienda Ospedaliera San Gerardo, Monza, Milano, Italy
Azienda Ospedaliera Umberto I, Ancona, , Italy
Hospital Clinico Universitario Virgen de la Victoria, Malaga, Andalucia, Spain
Hospital Universitari Vall d'Hebron, Barcelona, , Spain
Contact Details
Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
